ASPEN Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for ASPEN.

Overview

In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo^[1].

References

↑ Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006). “Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)”. Diabetes Care. 29 (7): 1478–85. doi:10.2337/dc05-2415. PMID 16801565. Review in: ACP J Club. 2006 Nov-Dec;145(3):62

[pmid16801565-1] Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006). “Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)”. Diabetes Care. 29 (7): 1478–85. doi:10.2337/dc05-2415. PMID 16801565. Review in: ACP J Club. 2006 Nov-Dec;145(3):62

[1]